Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Policy / Regulatory

China’s NMPA and NHC Implement New Rules for Temporary Import of Urgent Medical Devices

Fineline Cube Jul 22, 2024

The National Medical Products Administration (NMPA) and the National Health Commission have issued the Management...

Company Deals Drug

Jiangsu QYuns Therapeutics and Huadong Medicine Partner on QX005N Injection Development and Promotion

Fineline Cube Jul 22, 2024

Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has entered...

Company Drug

Innovent Biologics’ Mazdutide Achieves Primary and Secondary Endpoints in Phase III T2D Trial

Fineline Cube Jul 22, 2024

Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has announced...

Policy / Regulatory

China Unveils Ambitious Healthcare Reforms at 20th Central Committee Plenary Session

Fineline Cube Jul 22, 2024

The third plenary session of the 20th Central Committee of the Communist Party of China...

Company Drug

Jiangsu Hengrui Receives NMPA Approval to Study CDK 4/6 Inhibitor Dalpiciclib in Combination with HRS-1358 for Breast Cancer

Fineline Cube Jul 22, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has received...

Company Drug

Hansoh Pharmaceutical’s EGFR Inhibitor Ameile Files for Adjuvant Therapy Approval with NMPA

Fineline Cube Jul 22, 2024

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading biopharmaceutical company based in China, has...

Company Drug

NMPA Approves Chengdu Chipscreen’s Bilessglu for Type 2 Diabetes in Combination with Metformin

Fineline Cube Jul 22, 2024

The National Medical Products Administration (NMPA) has granted approval for Shenzhen Chipscreen Biosciences Co., Ltd...

Company Deals

Eisai Forges Partnerships with Chinese Firms to Strengthen Alzheimer’s Disease Market Presence

Fineline Cube Jul 22, 2024

Eisai Co., Ltd, (TYO: 4523) a Japanese pharmaceutical company, has announced separate strategic partnerships with...

Company Deals

MedSci Healthcare’s Bioon.com Partners with Wego Group to Boost Local Innovation and Product Promotion

Fineline Cube Jul 22, 2024

MedSci Healthcare Co., Ltd (HKG: 2415), a Chinese healthcare company, has announced that its subsidiary,...

Company Deals

Rona Therapeutics Secures USD 35 Million in Series A+ Round to Advance Nucleic Acid Therapies

Fineline Cube Jul 22, 2024

Rona Therapeutics, a Shanghai-based nucleic acid drug developer, has secured USD 35 million in a...

Company Deals

Huadong Medicine to Expand TCM Footprint with Acquisition of Hengba Pharmaceutical

Fineline Cube Jul 22, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced its intention to...

Company Deals

Beijing X-Magtech Secures Over RMB 100 Million in Series A+ Funding for Magnetic Field Measurement Tech

Fineline Cube Jul 22, 2024

Beijing X-Magtech Technologies, a specialist in ultra-weak magnetic field measurement technology, has reportedly secured over...

Company Deals

BGI Genomics and Technopark Biogen Launch Astana Genetic Center to Boost Genetic Testing in Central Asia

Fineline Cube Jul 22, 2024

Astana Genetic Center, a collaboration between China’s leading genomics company BGI Genomics Co., Ltd (SHE:...

Company Deals Drug

Apeiron Therapeutics Sells Rights to CDK7 Inhibitor GTAEXS617 to Exscientia for USD 30 Million

Fineline Cube Jul 22, 2024

Apeiron Therapeutics, a Shanghai-based biopharmaceutical company, has reached an agreement to sell all rights to...

Company Deals Digital Hospital

WeDoctor Partners with Shanghai Children’s Medical Center to Enhance Pediatric Care

Fineline Cube Jul 22, 2024

WeDoctor Holdings Ltd, a subsidiary of Chinese internet conglomerate Tencent Corporate Venture Capital (HKG: 0700)...

Company Drug

Bio-Thera Solutions Submits BLAs for Stelara Biosimilar BAT2206 to FDA and EMA

Fineline Cube Jul 22, 2024

Bio-Thera Solutions Ltd, a biopharmaceutical company based in Guangzhou, has announced the submission of Biologic...

Company

Novartis Delivers Strong Q2 2024 Results with 11% YoY Net Sales Increase

Fineline Cube Jul 19, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has released its financial results for the second...

Company Deals Drug

J&J Halts Development of Epilepsy Therapy ADX71149 After Phase II Trial Failure

Fineline Cube Jul 19, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a US-based multinational medical devices, pharmaceutical, and consumer packaged...

Company

Abbott Laboratories Reports Q2 2024 Sales Growth of 9.3%, Led by Medical Devices and Diabetes Sales

Fineline Cube Jul 19, 2024

Abbott Laboratories (NYSE: ABT), a global healthcare giant based in the US, has reported its...

Company Drug

Sino Biopharmaceutical Submits Market Approval Filing for CDK2/4/6 Inhibitor Culmerciclib in Breast Cancer

Fineline Cube Jul 19, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company in China, has announced the submission...

Posts pagination

1 … 379 380 381 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.